ILMN

ILLUMINA INC

Apr 05 • 04:00PM ET

83.62

+2.72 (+3.36%)

Company Profile

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenat ... read more

Full Time Employees 10,590

Phone 858 202 4500

Website https://www.illumina.com

CEO Mr. Jacob Thaysen Ph.D.

IPO Date 2000-07-28

Sector Healthcare

Industry Medical - Diagnostics & Research

Address 5200 Illumina Way, San Diego, CA 92122

Balance Sheet

Total Cash $1,113,000,000

Total Debt $2,529,000,000

Current Ratio 1.86

Quick Ratio 1.34

Profitability

Gross Margin 66.34%

Net Margin -22.25%

ROE -40.75%

ROA -15.61%

ROIC -12.37%

Balance Sheet

Total Cash $1,113,000,000

Total Debt $2,529,000,000

Current Ratio 1.86

Quick Ratio 1.34

Profitability

Gross Margin 66.34%

Net Margin -22.25%

ROE -40.75%

ROA -15.61%

ROIC -12.37%

Name	ILLUMINA INC	Sector	Healthcare	Currency	USD	Relative Volume	1.54	Market Cap	11746
Current Ratio	1.78	Dividend / Share	0.0	EPS	-7.69	Revenue	4372000000	P/S	2.7
P/E	-9.6	Beta	1.05	Income	-1223000000	Volume	3911528	Average Volume	2539153
Distance to 200DMA	-39.89%	200 DMA	123.38	50 DMA	97.54	ROA	-17.2	ROE	-41.9
Distance to 50DMA	-23.97%	Return 1Y	-40.28%	Return YTD	-44.5%	Forward PE		Qtly Growth YOY
Debt/Eq	1.66	P/B	5.0	Dividend Yield	0.0%	Net Margin	-27.97%	Payout Ratio	0.0

Performance

52 Week Range 0.0%

Distance to 200DMA 0.0%

Day Change Percent $0.00

Performance Range

Day

$196

Current

Low: High:

Month

$196

Current

Low: High:

Month

$196

Current

Low: High:

Month

$196

Current

Low: High:

Month

$196

Current

Low: High:

Balance Sheet

Total Cash $869,000,000

Total Debt $2,601,000,000

Current Ratio 2.43%

Quick Ratio 1.61%

Profitability

Valuation

Price to Earnings -13.78

Price to Book 5.61

Price to Sales 3.07

Price to Free Cash Flow 15.30

Dividends

Payout Ratio -0.00%

Dividend Yield 0.00%

Dividend Amount $0.00

Performance

52 Week Range 0.0%

Distance to 200DMA 0.0%

Day Change Percent $0.00

Company Profile

Full Time Employees 10,590

Phone 858 202 4500

Website https://www.illumina.com

CEO Mr. Jacob Thaysen Ph.D.

IPO Date 2000-07-28

Sector Healthcare

Address 5200 Illumina Way, San Diego, CA 92122

Histogram - Daily

Balance Sheet

Total Cash $869,000,000

Total Debt $2,601,000,000

Current Ratio 2.43%

Quick Ratio 1.61%

Profitability

Gross Margin 0.6390%

Net Margin -0.3610%

ROE -0.42%

ROA -0.20%

Company Profile

Full Time Employees 10,590

Phone 858 202 4500

Website https://www.illumina.com

CEO Mr. Jacob Thaysen Ph.D.

IPO Date 2000-07-28

Sector Healthcare

Address 5200 Illumina Way, San Diego, CA 92122

Monthly Win Rate

Balance Sheet (Multi-Column Example)

	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023	Jun 2023	Mar 2023
Cash & Short Term Investments	53,775.0	65,171.0	61,801.0	67,150.0	73,100.0	61,555.0	62,482.0	55,872.0
Receivables	59,306.0	66,243.0	43,172.0	41,150.0	50,102.0	60,985.0	39,186.0	35,899.0
Inventory	6,911.0	7,286.0	6,165.0	6,232.0	6,511.0	6,331.0	7,351.0	7,482.0

Latest News

Illumina To Webcast Upcoming Investor Conference

SAN DIEGO , May 14, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: 41st Annual Bernstein Strategic Decisi

2025-05-14 16:05:00 - prnewswire.com

Investing in Illumina (ILMN)? Don't Miss Assessing Its International Revenue Tre

Review Illumina's (ILMN) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

2025-05-13 10:21:48 - zacks.com

Illumina DRAGEN v4.4 powers clinical oncology research and multiomic application

Building on reputation for unparalleled performance, latest software delivers even greater accuracy, with 30% improvement in structural variant calling New features include easy-to-use oncology apps,

2025-05-13 09:15:00 - prnewswire.com

Illumina Analysts Lower Their Forecasts After Q1 Results

Illumina, Inc. ILMN reported upbeat earnings for the first quarter, but lowered its FY25 guidance, after the closing bell on Thursday.

2025-05-12 11:28:03 - benzinga.com

Illumina Q1 Earnings Top Estimates, Revenues Down Y/Y, Stock Dips

ILMN delivers better-than-expected earnings and revenues in the first quarter of 2025.

2025-05-09 09:50:42 - zacks.com

Illumina (ILMN) Tops Q1 Earnings and Revenue Estimates

Illumina (ILMN) came out with quarterly earnings of $0.97 per share, beating the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $0.09 per share a year ago.

2025-05-08 19:00:32 - zacks.com

Unveiling Illumina (ILMN) Q1 Outlook: Wall Street Estimates for Key Metrics

Beyond analysts' top -and-bottom-line estimates for Illumina (ILMN), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarte

2025-05-05 10:21:12 - zacks.com

Illumina (ILMN) Earnings Expected to Grow: Should You Buy?

Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2025-05-01 11:07:15 - zacks.com

Illumina and Ovation.io launching first-of-kind GLP-1 dataset to accelerate new

First real-world dataset with integrated clinical and multiomic insights from 25,000 patients treated with GLP-1 therapies Dataset will advance development of GLP-1 therapies in new indications and ac

2025-05-01 09:15:00 - prnewswire.com

Resmed Names Salli Schwartz as Chief Investor Relations Officer

Former Illumina, MSCI, and Moody's executive brings extensive experience leading engagement with the global investment community Former Illumina, MSCI, and Moody's executive brings extensive experienc

2025-04-21 17:00:00 - globenewswire.com

Target Validation for Genetic Targets Innovation Research Report 2025: 14,172 De

Dublin, April 18, 2025 (GLOBE NEWSWIRE) -- The "Innovation Insights: Target validation for genetic targets" report has been added to ResearchAndMarkets.com's offering.

2025-04-18 10:25:00 - globenewswire.com

Illumina and Tempus partner to drive the future of precision medicine through ge

Collaboration accelerates insights on clinical benefits of molecular profiling across all major categories of disease SAN DIEGO and CHICAGO , April 15, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN

2025-04-15 09:15:00 - prnewswire.com

Illumina to Announce First Quarter 2025 Financial Results on Thursday, May 8, 20

SAN DIEGO , April 10, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the first quarter 2025 following the close of market on Thursday, May 8, 2025. O

2025-04-10 16:05:00 - prnewswire.com

Here's Why Illumina (ILMN) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

2025-04-04 10:46:40 - zacks.com

Corvex's Meister joins the board at Illumina. Here's how he can create value for

Keith Meister, Corvex Management's chief investment officer, will join Illumina's board starting March 28. He's no stranger to the world of biotech.

2025-03-29 07:25:27 - cnbc.com

Is Illumina Undervalued After An 83% Drop In Its Stock Price?

The base and pessimistic DCF models implemented in this article suggest that Illumina is undervalued. Illumina expects to reach a growth rate in its revenues of 6%-9% CAGR by 2027. The DNA sequencing

2025-03-27 08:35:56 - seekingalpha.com